CHRS
Price
$1.33
Change
-$0.01 (-0.75%)
Updated
Dec 26 closing price
Capitalization
160.76M
80 days until earnings call
Intraday BUY SELL Signals
SLXN
Price
$2.29
Change
-$0.07 (-2.97%)
Updated
Dec 26 closing price
Capitalization
7.16M
Intraday BUY SELL Signals
Interact to see
Advertisement

CHRS vs SLXN

Header iconCHRS vs SLXN Comparison
Open Charts CHRS vs SLXNBanner chart's image
Coherus Oncology
Price$1.33
Change-$0.01 (-0.75%)
Volume$292.87K
Capitalization160.76M
Silexion Therapeutics
Price$2.29
Change-$0.07 (-2.97%)
Volume$36.17K
Capitalization7.16M
CHRS vs SLXN Comparison Chart in %
CHRS
Daily Signal:
Gain/Loss:
SLXN
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
CHRS vs. SLXN commentary
Dec 28, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CHRS is a Hold and SLXN is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Dec 28, 2025
Stock price -- (CHRS: $1.33 vs. SLXN: $2.29)
Brand notoriety: CHRS and SLXN are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CHRS: 27% vs. SLXN: 63%
Market capitalization -- CHRS: $160.76M vs. SLXN: $7.16M
CHRS [@Biotechnology] is valued at $160.76M. SLXN’s [@Biotechnology] market capitalization is $7.16M. The market cap for tickers in the [@Biotechnology] industry ranges from $117.45B to $0. The average market capitalization across the [@Biotechnology] industry is $2.21B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CHRS’s FA Score shows that 1 FA rating(s) are green whileSLXN’s FA Score has 1 green FA rating(s).

  • CHRS’s FA Score: 1 green, 4 red.
  • SLXN’s FA Score: 1 green, 4 red.
According to our system of comparison, CHRS is a better buy in the long-term than SLXN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CHRS’s TA Score shows that 5 TA indicator(s) are bullish while SLXN’s TA Score has 3 bullish TA indicator(s).

  • CHRS’s TA Score: 5 bullish, 2 bearish.
  • SLXN’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, CHRS is a better buy in the short-term than SLXN.

Price Growth

CHRS (@Biotechnology) experienced а -2.21% price change this week, while SLXN (@Biotechnology) price change was -4.58% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.36%. For the same industry, the average monthly price growth was +0.27%, and the average quarterly price growth was +54.56%.

Reported Earning Dates

CHRS is expected to report earnings on Mar 17, 2026.

Industries' Descriptions

@Biotechnology (+0.36% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CHRS($161M) has a higher market cap than SLXN($7.16M). CHRS has higher P/E ratio than SLXN: CHRS (2.42) vs SLXN (0.01). CHRS YTD gains are higher at: -3.623 vs. SLXN (-92.405). CHRS has higher annual earnings (EBITDA): 90.2M vs. SLXN (-9.24M). CHRS has more cash in the bank: 192M vs. SLXN (9.24M). SLXN has less debt than CHRS: SLXN (2.03M) vs CHRS (40.7M). CHRS has higher revenues than SLXN: CHRS (278M) vs SLXN (0).
CHRSSLXNCHRS / SLXN
Capitalization161M7.16M2,249%
EBITDA90.2M-9.24M-977%
Gain YTD-3.623-92.4054%
P/E Ratio2.420.0136,863%
Revenue278M0-
Total Cash192M9.24M2,077%
Total Debt40.7M2.03M2,010%
FUNDAMENTALS RATINGS
CHRS: Fundamental Ratings
CHRS
OUTLOOK RATING
1..100
22
VALUATION
overvalued / fair valued / undervalued
1..100
36
Fair valued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
6
PRICE GROWTH RATING
1..100
45
P/E GROWTH RATING
1..100
91
SEASONALITY SCORE
1..100
45

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
CHRSSLXN
RSI
ODDS (%)
Bullish Trend 4 days ago
90%
Bullish Trend 2 days ago
71%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 2 days ago
44%
Momentum
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
30%
MACD
ODDS (%)
Bullish Trend 2 days ago
79%
Bearish Trend 2 days ago
26%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
50%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
75%
Bullish Trend 2 days ago
30%
Advances
ODDS (%)
Bullish Trend 17 days ago
74%
Bullish Trend 24 days ago
52%
Declines
ODDS (%)
N/A
Bearish Trend 2 days ago
81%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
19%
Aroon
ODDS (%)
Bullish Trend 2 days ago
67%
Bearish Trend 2 days ago
70%
View a ticker or compare two or three
Interact to see
Advertisement
CHRS
Daily Signal:
Gain/Loss:
SLXN
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
EGLXF0.03N/A
+2.58%
Enthusiast Gaming Holdings Inc
ARGGY0.85N/A
+0.41%
Aston Martin Lagonda Global Holdings plc.
AHEXF26.35N/A
N/A
Adecco Group AG
PUBGY25.89-0.05
-0.19%
Publicis Groupe S.A.
SBNY1.20-0.15
-11.11%
Signature Bank (New York, NY)

CHRS and

Correlation & Price change

A.I.dvisor indicates that over the last year, CHRS has been loosely correlated with BEAM. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if CHRS jumps, then BEAM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CHRS
1D Price
Change %
CHRS100%
-0.75%
BEAM - CHRS
47%
Loosely correlated
-0.57%
VRDN - CHRS
44%
Loosely correlated
-1.24%
RXRX - CHRS
43%
Loosely correlated
-3.41%
XENE - CHRS
42%
Loosely correlated
-0.38%
XNCR - CHRS
41%
Loosely correlated
-1.49%
More

SLXN and

Correlation & Price change

A.I.dvisor indicates that over the last year, SLXN has been loosely correlated with IMA. These tickers have moved in lockstep 63% of the time. This A.I.-generated data suggests there is some statistical probability that if SLXN jumps, then IMA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SLXN
1D Price
Change %
SLXN100%
-2.97%
IMA - SLXN
63%
Loosely correlated
-0.85%
CELC - SLXN
53%
Loosely correlated
-0.35%
MRSN - SLXN
45%
Loosely correlated
-0.09%
CHRS - SLXN
26%
Poorly correlated
-0.75%
QSI - SLXN
25%
Poorly correlated
-6.11%
More